EU Recognizes Importance of ASI's Research on Developing New Smart Imaging Molecular Tools for Combating Neurodegenerative Diseases

The European Union's Seventh Framework Program (FP7) Research on the Brain and Related Diseases Funding the Framework Program for Research and Technological Development (RTD)

MIGDAL HAEMEK, Israel, February 16, 2010 - Neurodegenerative diseases such as Alzheimer's set a challenge
for modern medicine, as their origins are unclear and the comprehension of
the progression of symptoms often relies upon a patient's behavior.

Applied Spectral Imaging (ASI) (www.spectral-imaging.com/),
a leading provider of comprehensive imaging solutions for Pathology and
Cytogenetics, was chosen by the European Union (EU) to be one out of nine
industry and academia groups to form the Lupas consortium. ASI possess
unique spectral technology that labels each region of the image with multiple
colors beyond the basic red, green and blue colors that are available today
in digital cameras.

LUPAS seeks to develop new smart imaging molecular tools for
combating neurodegenerative diseases. Via modern imaging technology,
development and validation of novel, properly functionalized, luminescent
conjugated polymers (LCPs) can give rise to entirely new and innovative
methodology that can be used for biomedical research, diagnosis, monitoring
and prognosis, and for support and guidance of therapeutic interventions for
Alzheimer's disease and prior diseases. ASI harnesses its unique capabilities
within "Lupas" to help identify and characterize amyloids that form the
accumulation of plaques and proteins in the brain, usually associated with
Alzheimer patients.

The consortium is composed of expert groups in experimental
optics, polymer synthesis, magnetic resonance imaging (MRI), and synthesis of
functionalized magnetic nanoparticles, amyloid structure, AD mouse models,
clinical AD and prior diseases. This project establishes strategic links
between mainly SME based Industries, expert researchers at universities and
principal users in terms of hospitals. The project consortium will develop
and share an efficient plan for dissemination and exploitation of the project
results.

Limor Siphosh, CEO of ASI, "We hope that by the end of the third
year, we will have a better understanding of Alzheimer's disease, "mad cow
disease" and others. Knowledge will bring recognition and in time the ability
to accurately diagnose and treat these diseases."

About ASI

Applied Spectral Imaging (ASI), is a leading developer and manufacturer
of comprehensive solutions for Pathology and Cytogenetics imaging, computer
aided technology and data management needs. ASI was founded in 1993; it is a
privately held company with two fully owned subsidiaries that manage sales
and customer support in North America and Europe, along with independent
distributors throughout the rest of the world. The company owns more than 25
patents in the US alone, and other patents in Europe and Japan. These patents
cover general use spectral imaging, image analysis, scanning techniques,
spectroscopy in life science and medicine and patents for specific
applications.

For further information: www.spectral-imaging.com

Media Contact: IDAN Communications;

Keren Wulich: +972-9-9514666 or keren@idancom.com

Media Contact: IDAN Communications; Keren Wulich: +972-9-9514666 or keren at idancom.com